Mark Laughlin
Impact in
- Hepatology top 0.5%
- Hepatitis C virus research
- Epidemiology top 5%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
Papers in
-
- Hepatitis C virus research 7
-
- Liver Disease Diagnosis and Treatment 2
- Hepatitis B Virus Studies 1
- Co-authors
- Tobias Heintges (1 shared paper)Stuart C. Gordon (1 shared paper)Mitchell L. Shiffman (1 shared paper)Zachary Goodman (1 shared paper)Karen L. Lindsay (1 shared paper)Ruji Yao (1 shared paper)Eugene R. Schiff (1 shared paper)Janice K. Albrecht (1 shared paper)
- Journals
- Journal of Hepatology (3 papers)Hepatology (2 papers)AIDS (1 paper)Clinical Pharmacology & Therapeutics (1 paper)The Lancet (1 paper)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Mark Laughlin
12 papers receiving 1.2k citations
Mark Laughlin's Hit Papers
Peers
Comparison fields: 5 of 73
- Hepatology 908
- Epidemiology 610
- Virology 41
- Infectious Diseases 107
- Rheumatology 85
Countries citing papers authored by Mark Laughlin
This map shows the geographic impact of Mark Laughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Laughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Laughlin more than expected).
Fields of papers citing papers by Mark Laughlin
This network shows the impact of papers produced by Mark Laughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Laughlin. The network helps show where Mark Laughlin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Laughlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C Hit paper breakdown → | 2001 | 526 |
| 2 | 2010 | 250 | |
| 3 | 2005 | 107 | |
| 4 | 2008 | 97 | |
| 5 | 2006 | 90 | |
| 6 | 2001 | 50 | |
| 7 | 2002 | 45 | |
| 8 | 1994 | 29 | |
| 9 | 2010 | 14 | |
| 10 | 2010 | 7 | |
| 11 | 2005 | 5 | |
| 12 | A DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF ORAL VERSUS VAGINAL METRONIDAZOLE FOR THE TREATMENT OF TRICHOMONAL VAGINITIS | 1994 | 2 |
About Mark Laughlin
Mark Laughlin is a scholar working on Hepatology, Epidemiology, Infectious Diseases, Immunology and Genetics, having authored 12 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hepatitis C virus research (7 papers), Immunodeficiency and Autoimmune Disorders (2 papers), Liver Disease Diagnosis and Treatment (2 papers), HIV/AIDS drug development and treatment (2 papers), Chronic Myeloid Leukemia Treatments (1 paper), Antifungal resistance and susceptibility (1 paper), Urological Disorders and Treatments (1 paper) and Hepatitis B Virus Studies (1 paper). The work is most often cited by research in Hepatology (908 citations), Epidemiology (610 citations), Virology (41 citations), Infectious Diseases (107 citations) and Rheumatology (85 citations). Mark Laughlin has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Tobias Heintges, Stuart C. Gordon, Mitchell L. Shiffman, Zachary Goodman, Karen L. Lindsay, Ruji Yao, Eugene R. Schiff, Janice K. Albrecht, Christian Trépo and John C. Hoefs. Their work appears in journals such as Journal of Hepatology, Hepatology, AIDS, Clinical Pharmacology & Therapeutics and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.